Skip to content
OpenCapital
Get started

Aclaris Therapeutics ACRS Single Reportable — Research And Development Expense

Similar metrics at other companies

Celldex Therapeutics logo
CLDXSingle Reportable — Research And Development Expense
$73M+38.7%
Capricor Therapeutics logo
CAPRSingle Reportable — Research And Development Expense
$27.38M+44.7%
Iovance Biotherapeutics, Inc. logo
IOVASingle Reportable — Research And Development Expense
$57.37M-13.1%
Merit Medical Systems logo
MMSISingle Reportable — Research And Development Expense
$22.61M+0.6%
Alumis Inc. logo
ALMSSingle Reportable — Research And Development Expense
$81.54M-15.6%
908 Devices logo
MASSSingle Reportable — Research And Development Expense
$3.47M-9.3%

Other financials

Income statement

See full
Revenue$2.0M+37.2%
Gross profit$1.6M+68.7%
Operating income-$22.2M-22.7%
Net income-$19.8M-31.4%
EPS (diluted)-$0.15-25.0%

Balance sheet

See full
Cash & equivalents$28.7M-5.6%
Total debt$2.0M-20.1%
Total equity$143.6M-0.3%
Total assets$198.7M+0.3%

Cash flow

See full
Operating cash flow-$18.1M-39.0%
CapEx$13.0K-69.8%
Free cash flow-$18.2M-38.6%

Valuation

See full
Market cap$685.75M+337%
Enterprise value$659.07M+410%
P/S82×+73.1×

Profitability

See full
Gross margin76.3%-9.7pp
Operating margin-961.9%+259pp
Net margin-832.6%+132pp
FCF margin-624.9%—

Returns & leverage

See full
Return on equity-48.4%-15.4pp
Debt / equity0×0.0×
Current ratio4×-1.0×

Where this comes from

Reported directly by Aclaris Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The official record: Aclaris Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Aclaris Therapeutics's single reportable — research and development expense.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Aclaris Therapeutics's single reportable — research and development expense?
Aclaris Therapeutics (ACRS) reported single reportable — research and development expense of $15.66M in Q1 2026.
How has Aclaris Therapeutics's single reportable — research and development expense changed year-over-year?
Aclaris Therapeutics's single reportable — research and development expense increased by 35.2% year-over-year, from $11.58M to $15.66M.
What does single reportable — research and development expense mean?
The aggregate expenditure incurred by the segment for research and development activities, including both personnel and operational costs. This is a critical metric for biopharmaceutical companies to track the total burn rate associated with pipeline development. It reflects the overall strategic focus on bringing new therapies to market.